Clinical Studies on Familial Adenomatous Polyposis by Heiskanen, Ilkka
Department of Surgery
Helsinki University Central Hospital
University of Helsinki
Helsinki, Finland





To be publicly discussed by permission of the Medical Faculty of the
University of Helsinki in auditorium 2, University Central Hospital at
Meilahti, on September 15th, 2000, at 12 noon.
Helsinki 2000
Supervised by:
























LIST OF ORIGINAL PUBLICATIONS  6
ABBREVIATIONS  7
INTRODUCTION  8
REVIEW OF THE LITERATURE  9
















Congenital hypertrophy of retinal pigment
epithelium 19
Skin and bone 19






Proctocolectomy and ileostomy 22
Colectomy and ileorectal anastomosis 22
Restorative proctocolectomy 23
Desmoid disease 23
Upper gastrointestinal tract 24
Postoperative surveillance 25
After bowel surgery 25
Upper gastrointestinal tract 25
AIMS OF THE PRESENT STUDY 26
PATIENTS AND METHODS 27
Type of operation (I) 27
Rectal remnant after surgery (II) 28
Desmoid tumors (III) 29




Outcome of colectomy (I) 32
Rectal remnant after surgery (II) 32
Desmoid tumors (III) 35
Duodenal polyposis (IV) 36
Survival (V) 37
DISCUSSION 40
Choice of operation 40
The rectal stump 41
Management of desmoid tumors 42
Treatment of gastroduodenal lesions 44







6LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following original publications, referred to in the text by
Roman numerals:
I Heiskanen I, Matikainen M, Hiltunen K-M, Laitinen S, Rintala R, Järvinen
HJ. Colectomy and ileorectal anastomosis or restorative proctocolectomy
for familial adenomatous polyposis. Colorect Dis 1999;1:9-13.
II Heiskanen I, Järvinen HJ. Fate of the rectal stump after colectomy and
ileorectal anastomosis for familial adenomatous polyposis. Int J Colorect Dis
1997;12:9-13.
III Heiskanen I, Järvinen HJ. Occurrence of desmoid tumours in familial
adenomatous polyposis and results of treatment. Int J Colorect Dis
1996;11:157-162.
IV Heiskanen I, Kellokumpu I, Järvinen HJ. Management of duodenal
adenomas in 98 patients with familial adenomatous polyposis. Endoscopy
1999;31:412-416.
V Heiskanen I, Luostarinen T, Järvinen HJ. Impact of screening examinations
on survival in familial adenomatous polyposis. Scand J Gastroenterol,
accepted for publication.
7ABBREVIATIONS
AAPC attenuated adenomatous polyposis coli
AFAP attenuated adenomatous polyposis coli
APC adenomatous polyposis coli
CAPP concerted action for polyposis prevention
CHRPE congenital hypertrophy of the retinal pigment epithelium
COX cyclooxygenase inhibitor
CRC colorectal cancer
DCC deleted in colon cancer gene
DNA deoxyribonucleic acid
DT desmoid tumor
FAP familial adenomatous polyposis
FGP fundic gland polyp
GS Gardner's syndrome
HNPCC hereditary nonpolyposis colorectal cancer
IRA colectomy and ileorectal anastomosis
NSAID nonsteroidal anti-inflammatory drug
PC proctocolectomy
PC+I proctocolectomy and ileostomy
PTT protein truncation test
p53 tumor suppressor gene protein p53
RPC restorative proctocolectomy, proctocolectomy with ileal pouch 
anal anastomosis
8INTRODUCTION
Familial adenomatous polyposis (FAP) is an autosomally dominant inherited
disease with 50% risk in every offspring and equal distribution between the two
sexes. Typically, FAP patients develop from hundreds to thousands of
adenomatous polyps in the colon or rectum, but the disease does not usually
manifest until late childhood or early adult life. One or a few of these benign
polyps almost inevitably develop into colorectal carcinoma (CRC) (Bussey, 1975).
However, FAP is a systemic disorder affecting tissues from all three germ layers,
with various extracolonic manifestations: ectodermal (skin cysts, eye lesions, and
endocrine tumors), endodermal (liver tumors, adenomas, and adenocarcinomas of
the stomach, small bowel, and biliary tree) and mesodermal (dental abnormalities,
desmoids, and osteomas) (Talbot, 1994).  
The polyposis varies in severity in different families. Because of the inevitable risk
of CRC in an untreated FAP patient, screening of individuals at risk begins at
puberty with annual colonic examinations and prophylactic colectomy is indicated
before symptomatic disease or with diffuse polyposis (Bussey, 1975).
Centralized registration of polyposis patients, screening of family members at risk,
and early colectomy has led to improvement of the prognosis (Bülow et al, 1995b).
As deaths from colorectal cancer remain constant or decrease in frequency, it is
likely that proportional death rates from extracolonic manifestations of FAP will
continue to rise (Belchetz et al., 1996). However, there are controversies over
treatment methods. The present study was undertaken to study therapeutic
strategies, results of treatment, and survival of patients with FAP.
9REVIEW OF THE LITERATURE
History and nomenclature
In 1721, Menzel published the first known report of a polypoid condition, but it
was probably of inflammatory origin (Menzel 1721). In 1881, Sklifasowski reported
the first definite case of FAP and in 1882 Cripps recorded polyposis in a brother
and sister, suggesting a familial tendency of the disease (Sklifasowski 1881;
Cripps, 1882). The change from a polyp to carcinoma was described in 1890 by
Hanford and in 1895 in a review by Hauser (Hanford, 1890; Hauser, 1895).
In 1925, Lochart-Mummery investigated three families with multiple adenomata,
which was also the start of St Mark's Polyposis Register (Bussey, 1975). The
autosomal dominant inheritance was described by Cockayne (Cockayne, 1927).
The clinical, genetic, and pathological aspects of familial polyposis coli were more
accurately defined in the 1950s and 1960s. Gardner described a kindred with
polyposis, multiple osteomas, and epidermoid cysts, a disease entity called
Gardner's syndrome (GS) (Gardner, 1951; Gardner and Richards, 1953), which he
considered to be a distinct genetic disorder. Later on, desmoid tumors and dental
abnormalities were also included (Gardner, 1962). Many authors considered GS to
be a variant form of the same genetic disorder, thus representing a combination of
different extracolonic manifestations of FAP (Smith, 1968; Utsunomiya and
Nakamura, 1975; Watne et al., 1975).
In 1975, Alm described the results of treatment of familial polyposis coli based on
the first national registry (Alm, 1975a; 1975b). Bussey published a detailed
description of FAP in his extensive monograph in 1975 (Bussey, 1975).
In 1986, Herrera and coworkers detected an interstitial deletion in the long arm of
chromosome 5 in a patient with GS (Herrera et al., 1986). In 1987, the FAP locus was
localized by linkage analysis to the region of 5q21-22 (Bodmer et al., 1987; Leppert
et al., 1987). In 1991, the adenomatous polyposis coli gene (APC) was
subsequently localized and the gene sequence defined (Groden et al., 1991; Kinzler
et al., 1991; Nishisho et al., 1991).
FAP has been synonymous with disseminated polypi (Cripps, 1882), polyposis
intestinalis adenomatosa (Hauser, 1895), polyposis intestini (Dukes, 1930), familial
adenomatosis of the colon and rectum (Lockhart-Mummery and Dukes, 1939),
familial intestinal polyposis (Dukes, 1952), familial multiple polyposis (Smith, 1968),
hereditary adenomatosis of the colon and rectum (Alm and Licznerski, 1973;
Painter and Jagelman, 1985), familial polyposis of the colon (Lockhart-Mummery et
al., 1956; Yao et al., 1977), adenomatous polyposis of the gastrointestinal tract
(Hamilton et al., 1979), and familial adenomatous polyposis coli (Järvinen, 1987).
10
However, it became obvious that the most common term, familial polyposis coli,
was inappropriate because of the various extracolonic manifestations. Therefore,
the Leeds Castle Polyposis Group advocated the term familial adenomatous
polyposis (FAP) (Thomson, 1987).
Registries
The first polyposis register was started in 1925 at St Mark's Hospital, London, at
the initiation of JP Lockhardt-Mummery, C Dukes, and HJR Bussey (Bussey, 1975).
During the last 30 years, national and regional registers have been established
round the world (Jagelman, 1983; Berk et al., 1987; Bülow, 1987; Macrae et al., 1989;
Morton et al., 1993), the Finnish Polyposis Registry was started in 1984 (Järvinen
et al., 1984). Since the foundation of the registries, the incidence of colorectal
cancer has decreased from 50-70% of patients detected by bowel symptoms to 3-
10% of patients detected by screening (Alm and Licznerski, 1973; Bülow, 1987;
Vasen et al., 1990).
Ideally, registries are run by a combination of surgeons, gastroenterologists and
geneticists. Research work is part of the registrar's work, both nationally and
internationally. Therefore, a collaborative group of specialists founded "The Leeds
Castle Polyposis Group" for further co-operative studies on FAP (Northover,
1987).
Epidemiology
The most reliable data on incidence and prevalence are from countries with
national parish registries, as in the Nordic countries. The frequency at birth has
been reported to be 1:7600 to 1:22000 (Alm and Licznerski, 1973; Järvinen et al.,
1984; Bülow, 1987). The prevalence has been 2.29-2.62x10-5 (Burn et al., 1991;
Maher et al., 1993). An incidence of 1 in 10,000 live births and a prevalence of 1 in
30,000 can be used as approximations.
Pathology
Adenomas of the large intestine are tubular adenomas arising from the mucus-
secreting epithelium lining the interior of the intestine. Polyps are usually scattered
throughout the colon and their size may vary, but most of them are under 5 mm in
diameter. Some polyps may be pedunculated and others sessile. Adenomatous
polyps rarely become manifest before 10 years of age. (Talbot, 1994)
Most colorectal carcinomas arise from a pre-existing adenoma, forming
anadenoma-carcinoma sequence, as proposed by Muto and coworkers (Muto et
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al. 1975). The adenoma-carcinoma sequence pertains to the duodenum as well as to
the large bowel (Spigelman et al., 1994).
Knudson suggested a "two-hit" hypothesis of cancer formation: in the dominantly
inherited form, one mutation is inherited in the germline cells and the normal copy
of the gene is inactivated by a second mutation ("second hit") in somatic cells
(Knudson, 1971). In accordance with this hypothesis, Vogelstein and colleagues
have described a genetic model for tumorigenesis in colorectal cancer (Fearon and
Vogelstein, 1990; Kinzler and Vogelstein, 1996). The APC gene mutation initiates
the neoplastic process and tumor progression results from genetic changes, including
oncogene activation (K-ras) and inactivation of tumor suppressor genes (APC, DCC,
p53) (Fig. 1).
Genetics
In 1986, Herrera and coworkers detected an interstitial deletion of the long arm of
chromosome 5 in a patient with Gardner's syndrome (GS) (Herrera et al., 1986).
Thereafter the FAP locus was localized to the region of 5q21-22 in 1987 (Bodmer et
al., 1987; Leppert et al., 1987). Thus, the diagnosis of FAP was possible by
predictive DNA markers closely linked to the gene, but was dependent on the
availability of DNA from other family members (Tops et al., 1989). However, it
only gives an estimation of the risk of being a gene carrier rather than a definite risk.
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The adenomatous polyposis coli (APC) gene was localized and gene sequencing
performed in 1991 (Groden et al., 1991; Kinzler et al., 1991; Nishisho et al., 1991).
Thereafter, the diagnosis of FAP was possible by mutation analysis. This gene on
chromosome 5q21-22 consists of 15 exons and encodes a polypeptide protein of
2843 amino acids. It is considered to function as a tumor suppressor gene. The
majority of mutations of the APC gene cause a stop codon via point mutations or
frameshifts resulting in a truncated protein (Nishisho et al., 1991; Miyoshi et al.,
1992). Over 300 mutations have been reported (van der Luijt et al., 1996).
The APC gene protein forms a complex with a protein kinase. This complex targets
for degradation of b-catenin, a protein involved in both cell adhesion and
intracellular signal transduction. It is also involved in cell migration up the colonic
crypt and cell adhesion through association with E-cadherin. (Kinzler and
Vogelstein, 1996)
Penetrance, however, has been incomplete (Reed and Neel, 1955; Alm and
Licznerski, 1973). Spontaneous mutation has been reported in up to 46% of FAP
cases, and is associated with a more severe form of the disease, probably due to
later diagnosis (Rustin et al., 1990; Vasen et al., 1990; Maher et al., 1993). These
individuals are as likely to transmit the disease to their children as individuals with
a family history.
Genotype-phenotype correlations
Several studies have shown a correlation between a specific mutation of the APC
gene and the phenotypic expression (Nagase and Nakamura, 1993; Fodde and
Khan, 1995; van der Luijt 1996). However, individuals with identical mutations may
show variability in polyp count and extracolonic manifestations (Nagase and
Nakamura, 1993; Giardiello et al., 1994). Mutations nearer the 5' end of the APC
gene are associated with small numbers of colorectal adenomas and late onset of
CRC, described as an attenuated form of FAP (AAPC) (Spirio et al., 1993; Soravia
et al., 1998). Lynch and coworkers described a syndrome of sparse and flat
adenomas located in the proximal colon and upper gastrointestinal lesions, which
was termed hereditary flat adenoma syndrome (HFAS) (Lynch et al., 1992). The
clinical picture, pathologic features, and genetic studies of HFAS revealed it to be
the attenuated form of FAP (Lynch et al., 1995a). Mutations at codon 1597 or
beyond also produce an attenuated phenotype (Friedl et al., 1996). Profuse
polyposis and earlier onset of CRC have been associated with a deletion in codon
1309 (Caspari et al., 1994) and with mutations between codons 1250 and 1464
(Nagase et al., 1992). Extracolonic manifestations were correlated with mutations
beyond codon 1403 and severe gastroduodenal polyposis with a mutation at




Modifier gene(s) and environmental factors interact with the disease-causing APC
gene mutation and may be responsible for genotype-phenotype variations (Fodde
and Khan, 1995; Sanabria et al., 1996). Characterization of the causative mutation
will probably have significant effects on management. In the future, it may be
possible to adjust counselling, surveillance, and treatment according to the
genotype (Cunningham and Dunlop, 1996; Vasen et al., 1996; Soravia et al., 1998).
Genetic counselling
The diagnosis and treatment of FAP have caused great distress in an affected
family in the past. Due to lack of an early diagnosis, of effective treatment and of
satisfactory results, collaboration with families was difficult. In addition, the
extracolonic manifestations may even lead to social problems (Gardner, 1951). The
advances in surgical treatment and management of complications with a more
precise knowledge of polyposis have made it much easier to keep in touch with the
families. It is important to recognize that the management of the first individual still
has a crucial influence on other family members (Mills et al., 1997).
The counselling of FAP patients is often complex and difficult (Macrae et al., 1989;
Burn et al., 1991; Greely, 1999). The priorities of genetic testing in adults and
children are different. Testing should not be offered to a child until the age of first
possible onset of cancer (Kodish, 1999). Genetic counselling of the tested
individual must always accompany a gene test, preferably by a clinician or a
geneticist personally to the individual tested. The benefit for the person at risk,
and for the parents, is reduction of uncertainty and increased compliance with
screening. There have not been serious adverse psychological reactions after
disclosure of the gene test results but this possibility must be taken into account
(Petersen, 1994). However, the inappropriate use of genetic testing carries the risk
of misinterpretation and even false-negative results (Giardiello et al., 1997).
The protein truncation test (PTT) can be used to clarify the genetic status of at-
risk family members with certainty if a clinically diagnosed relative has undergone
PTT and is known to have a truncated APC protein (van der Luijt, 1996). Linkage
analysis can be considered in families with more than one affected family member
who belong to different generations and with availability of the family members to
be tested. These same criteria are met with prenatal testing. However, detection of
the mutation does not predict the onset or severity of the disease.
Diagnosis and family screening
The definition proposed by Bussey states that "adenomatous polyposis coli is an
inheritable condition in which the large intestine contains multiple adenomas,
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multiple being defined as more than 100" (Bussey, 1975). This can no longer be a
strict criterion in young patients (Bülow, 1991). Microscopic examination is
mandatory to define the adenomatous nature of the polyps.
Diagnosis and screening of individuals at risk should include the medical history, a
clinical examination, and bowel examination by flexible sigmoidoscopy from the age
of 10-14 years with a further colonoscopy if adenomas are found (Berk et al., 1987;
Dozois, 1988; Bülow, 1991). Regular examination at 2-3 year intervals should
continue up to the age of 60 years, even if the endoscopies are negative, in order
to exclude late onset of the disease. Upper gastrointestinal tract endoscopy should
be done with patients over the age of 20 years for possible gastroduodenal
polyposis with adequate biopsies when FAP has been diagnosed. Patients with
adenomas should have endoscopy every 1-2 years and without adenomas every 5
years (Bülow, 1991).
Presymptomatic diagnosis of individuals at risk is of importance (Burt and Groden,
1993; Powell et al., 1993). Skin cysts, osteomas, and CHRPE may preceed the
development of intestinal adenomas. These may be simple, noninvasive and
inexpensive markers of gene carriers (Leppard and Bussey, 1975; Bülow et al.,
1984). CHRPE is an interesting clinical marker of gene carriers with an approximate
sensitivity and specificity of 85% and 98%, respectively (Traboulsi et al., 1987;
Baba et al., 1990).
Various mutations of the APC gene are accurately detected by linkage analysis for
carrier status (Burt and Groden, 1993; Nagase and Nakamura, 1993) but the optimal
method is mutation analysis (Cunningham and Dunlop, 1996). For FAP families
with an apparent new mutation or when family members are not available for
linkage analysis, direct mutation analysis is the only choice (Bapat et al., 1994).
Antibodies against APC products are useful for direct analysis of the truncated
APC protein (van der Luijt, 1996). The commercially available test has a sensitivity
of 80%, and virtually 100% when the mutation in the family is known (Powell et al.,
1993; Cromwell et al., 1998). Differences in the APC mutations alone cannot solely
account for the genotype-phenotype correlations. Therefore, classically described
surveillance and prophylactic treatment methods do not apply to all patients with
FAP (Lynch and Smyrk, 1998).
If a presymptomatic mutation of the APC gene is identified, no change in screening
guidelines is recommended. Without an inherited APC mutation, screening can be
reduced or omitted (Petersen, 1994; Kinzler and Vogelstein, 1996). In addition to
the clinical benefits of the molecular genetic diagnosis, the reduction of screening




FAP is characterized by development of adenomas at the age of puberty, with the
subsequent development of CRC at a young age. There may be a history of
slightly increased bowel frequency with loose stools. Typical symptoms of FAP
are rectal bleeding, diarrhea, abdominal pain, mucous discharge and constipation.
In spite of numerous polyps, patients may be asymptomatic. Every symptomatic
patient should have a total colonoscopy with multiple biopsies in order to find
polyps and to exclude colon cancer.
Adenomatous polyps usually antedate the development of colorectal cancer by
10-20 years. In an untreated patient, adenomas first become apparent at the age of
20 years. Bowel symptoms occur by the age of 29 years, the diagnosis of FAP is
made 3-5 years later, colorectal cancer appears 7-8 years later, and death due to
colorectal cancer in the early forties. However, the ages of manifestations have
wide limits. (Alm and Licznerski, 1973; Bussey, 1975; Bülow, 1987)
Extracolonic lesions
When carefully examined clinically, endoscopically and radiologically a high
proportion of FAP patients have some of a variety of extracolonic manifestations,
(Table 1).
Desmoid tumors
Desmoid tumors (DTs) are lesions originating from the musculoaponeurotic tissue
in the abdominal wall, the mesentery or the extremities or trunk. Typically, a DT has
an ill-defined margin and lacks encapsulation. Microscopically, it is acellular, with
dense hyalinized areas, but a few are more aggressive. They may involve the
mesentery and the retroperitoneal space, which can lead to venous infarction,
intestinal obstruction, or hydronephrosis, and may even have a fatal outcome.
(Farmer et al., 1994)
DTs are very rare, with an incidence of 2-4 per million (Reitamo et al., 1986). FAP
patients develop DTs with a frequency of between 7 and 14% (Jones et al., 1986;
Iwama et al., 1993; Penna et al., 1993d), a risk 852 times that of the general
population (Gurbuz et al., 1994). When the risk of colon cancer is reduced, the
importance of the desmoid disease increases, as may its frequency. DT can
antedate the diagnosis of polyposis, and therefore patients with DTs should be
examined for polyposis (McAdam and Goligher, 1970). Family clustering has been
clearly documented (Penna et al., 1993d; Gurbuz et al., 1994).
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Table 1. Extracolonic manifestations of FAP (Parks et al., 1970, Talbot, 1994).
Ectodermal origin Mesodermal origin Endodermal origin
Epidermoid cysts Connective tissue Adenomas of
Tumors of the Fibroma and  fibrosarcoma Stomach
central nervous system Desmoid tumors Duodenum
Congenital hypertrophy Diffuse fibrosis Hepatopancreaticobiliary
of retinal pigment Excessive intra-abdominal    tract
epithelium    adhesions Small intestine
Thyroid gland
Bone Endocrine tissue
Osteoma    adrenal, parathyroid,






Supernumerary teeth    tract





The factors presumed to precipitate desmoid formation include surgical trauma,
pregnancies, and other hormonal influences (Gurbuz et al., 1994). APC gene
mutations are associated with DTs and other extracolonic manifestations (Caspari
et al., 1995; van der Luijt 1996) in contrast to earlier registry analysis (Gurbuz et al.,
1994). Other poorly understood factors also influence the risk of DT. Recently,
Clark and coworkers proposed a model of DT development in which a less benign
phenotype emerges as molecular genetic abnormalities accumulate. In many
patients with FAP, mesenteric plaque-like desmoid precursor lesions arise before
surgery as a result of abnormal fibroblast function (Clark et al., 1998). Some,
perhaps stimulated by surgery, progress to mesenteric fibromatosis and these, in
turn, can give rise to DTs.
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Upper gastrointestinal tract
The association of gastroduodenal polyps with polyposis has been known for
over a century (Hauser, 1895). In 1935, Cabot reported a patient with a carcinoma of
the ampulla of Vater and MacDonald described malignant degeneration in a case of
duodenal polyposis (Cabot, 1935; Macdonald et al., 1967). Gardner noticed
occasional involvement of the stomach in his series (Gardner and Richards, 1953).
McKusick stated that polyps could occur anywhere in the gastrointestinal tract
(McKusick, 1962) and an association with gastric carcinoma was reported by
Murphy (Murphy et al., 1962). In an extensive analysis of GS, the frequency of
periampullary cancer was 2-3%, representing a risk 100- to 200-fold that of the
general population (Pauli et al., 1980).
In 1971, Hoffman and Goligher described polyposis of the stomach and small
intestine (Hoffmann and Goligher, 1971). Utsunomiya found gastric polyps in 67%
of patients with FAP (Utsunomiya et al., 1974). Since then, many groups have
pointed out the high incidence of both gastric and duodenal polyps in FAP (Yao et
al., 1977; Järvinen et al., 1983b; Jagelman et al., 1988; Church et al., 1992; Offerhaus
et al., 1992). Therefore, upper gastrointestinal endoscopy is included as part of the
diagnostic workup and surveillance program (Sarre et al., 1987; Spigelman et al.,
1989), although this is not without critics (Norfleet, 1992).
Stomach
Watanabe was the first to describe gastric fundic gland polyps (FGPs) (Watanabe
et al., 1978). FGPs consist of hyperplasia of the fundic gland and microcysts. They
are rare except in FAP, with considerably variation in number and size (Iida et al.,
1984). FGP have been considered to be benign lesions with no apparent
relationship to neoplasia (Talbot, 1994). Gastric adenomatous polyps are usually
limited to the antrum. If adenomas are found endoscopic surveillance, every 1-2
years, has been recommended but at longer intervals if only FGP are found (Bülow,
1991). Interestingly, FGP occasionally exhibit adenomatous changes, implying a
potential risk of gastric cancer (Zwick et al., 1997; Wu et al., 1998c).
Duodenum
Duodenal or periampullary cancer is an important cause of death in FAP (Arvanitis
et al., 1990; Iwama et al., 1993). Endoscopies, preferably with a side-viewing
endoscope, with numerous random biopsies of the ampulla and periampullary
region, should be done at least every three years. If there are large or dysplastic
adenomas, endoscopies should be done annually and, with severe dysplasia or
numerous large polyps, surgery should be considered (Iida et al., 1989b). No
genotype-phenotype correlations between the severity of periampullary polyposis
and the specific germline mutation have been found, but there may be family
segregation in the occurrence of periampullary malignancy (Sanabria et al., 1996).
19
The high prevalence of adenomas and carcinomas at or near the papilla of Vater
and in the small bowel, which are exposed to high bile acid concentrations, as well
as studies of bile acids, suggest that bile affects the formation of small bowel and
colorectal cancer (Spigelman et al., 1989; Hill, 1991).
Small bowel
The presence of small bowel polyposis is uncommon and the exact incidence is
unknown. Ross and Mara reported primary adenocarcinomas in the small bowel
and suggested initial and periodical small intestinal examinations (Ross and Mara,
1974). Ileal adenomas and carcinomas have been found after colectomy (Ohsato et
al., 1977; Hamilton et al., 1979; Roth and Logio, 1982; Iida et al., 1989a) and minute,
asymptomatic adenomas with a push-type jejunal endoscope (Iida et al., 1990;
Bertoni et al., 1993). According to these studies, the small intestine should be
examined before surgery and periodically afterwards.
Congenital hypertrophy of the retinal pigment epithelium (CHRPE)
Retinal pigment abnormalities were noted in 1935 (Cabot, 1935). In 1980, Blair and
Trempe found an association between these retinal pigment abnormalities and GS,
later on referred as CHRPE (Blair and Trempe, 1980). The CHRPE lesions are darkly
pigmented, round lesions with hypertrophied cells filled with melanosomes. There
may be a hypopigmented halo around the periphery or depigmented lacunae within
the lesions. Four or more lesions in one or both eyes are specific for FAP with a
familial consistency in the number of lesions in the affected pedigrees and with a
specificity of 98% and a sensitivity of 85% (Lynch et al., 1987; Traboulsi et al.,
1987; Romania et al., 1989).
CHRPE is assocated with mutations between codons 463 and 1387 (Olschwang et
al., 1993). The presence of this marker varies from two thirds to all FAP kindreds
(Romania et al., 1989). CHRPE are detectable at a very early age with a direct,
noninvasive and inexpensive ophthalmological examination, but a negative
examination in an young, unaffected individual does not mean that rectal screening
can be omitted (Berk et al., 1988).
Skin and bone
Gardner described the soft tissue tumors in FAP (Gardner, 1951; Gardner, 1962).
They are mostly epidermoid cysts throughout the body but lipomas, sebaceous
cysts, and neurofibromas are also encountered. In children, epidemoid cysts,
especially of the face and extremities, are typical for FAP (Leppard and Bussey,
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1975). Skin cysts as well as osteomas can preceed the development of intestinal
adenomas (Gardner, 1962; Leppard and Bussey, 1975; Offerhaus et al., 1987).
Osteomas of the jaw are usually multiple, small, well-circumscribed, and often
palpable radiodensities in the molar regions of the maxilla and mandible. Other
dental abnormalities have also been found, including supernumerary teeth,
unerupted teeth, odontomas, dental cysts, early onset of caries, and loss of teeth.
(Utsunomiya and Nakamura, 1975)
Liver and the biliary tract
There are reports of biliary adenomas and carcinomas of the liver, gallbladder, bile
duct, and pancreas (Lees and Hermann, 1981; Järvinen et al., 1983a; Willson et al.,
1987). Childhood hepatoblastoma is a rare malignant embryonal tumor associated
with FAP. Clinical awareness has been recommended and also screening
(Giardiello et al., 1991).
Thyroid gland
Thyroid carcinomas have been associated with FAP (Camiel et al., 1968; Alm and
Licznerski, 1973). They are mostly multicentric at an early age and present with
extracolonic manifestations. The relative risk of thyroid carcinoma has been 20-160-
fold in FAP. Therefore, regular clinical examinations of the thyroid gland with use
of ultrasound were recommended (Plail et al., 1987; Giardiello et al., 1993b) but
seemed unjustified in a recent registry report (Bülow and Bülow, 1997).
Other neoplasms
Various extracolonic neoplasms have been reported in FAP: carcinoid tumors,
adrenal adenomas, and carcinomas (Macdonald et al., 1967; Naylor and Gardner,
1981; Painter and Jagelman, 1985; Marchesa et al., 1997), pancreatic neoplasms
(Schneider et al., 1983; Giardiello et al., 1993b), parathyroid adenomas (Naylor and
Gardner, 1981; Schneider et al., 1983), pituitary adenomas (Naylor and Gardner,
1981; Schneider et al., 1983), urinary bladder cancer (Watne et al., 1975), and
carcinoma of the uterus and ovary (Watne et al., 1975).
Turcot et al found an association between familial polyposis and malignant tumors
of the central nervous system (Turcot et al., 1959). In addition, registry evidence
suggested that brain tumors were an early extracolonic manifestation of FAP
(Kropilak et al., 1989). In subsequent studies, however, Turcot syndrome seemed
to be genetically distinct from FAP (McKusick, 1962; Itoh et al., 1979). Tops and
coworkers showed that the APC gene was not involved (Tops et al., 1992).
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Nevertheless, it has been later demonstrated that brain tumors do occur in
association with both FAP (predominantly medulloblastomas) and HNPCC
(predominantly glioblastoma multiforme) (Hamilton et al., 1995; Aarnio et al., 1999).
Treatment
Medical treatment
Various nutritional and metabolic trials have been made. A high-fiber diet with
vitamins C and E had a limited regression potential on rectal adenomas (Bussey et
al., 1982; DeCosse et al., 1989). However, the strong inverse association between
starch intake and CRC suggests an important role for starch in prevention of CRC
(Cassidy et al., 1994). The ongoing CAPP study probably reveals the effect of
aspirin and starch on FAP (Burn et al., 1995). Oral calcium has had an inconsistent
effect on the risk of colon cancer (Stern et al., 1990; Thomas et al., 1993) and may,
in fact, be harmful in FAP (Paraskava, 1992).
An NSAID (e.g. sulindac) reduces mucosal proliferation activity, with significant
polyp regression and without side effects (Waddell et al., 1989; Labayle et al.,
1991). Polyp regression was also found after IRA, with progression after omitting
sulindac (Giardiello et al., 1993a). Sulindac restricts prostaglandin synthesis and
reactivates the cyclic AMP- dependent control of cell growth (Waddell, 1994). In
recent studies, NSAIDs have inhibited the growth of colon cancer cell lines
independently of prostaglandins, probably by the apoptotic pathway (Giardiello et
al., 1998).
Sulindac is a possible treatment of rectal polyposis after IRA and for patients
unsuitable for the pouch procedure (Setti-Carraro and Nicholls, 1996). However,
the effect has only been temporary and diminution of the adenomas did not
exclude the development of cancer (Lynch et al., 1995b; Giardiello et al., 1998).
Thus, whether sulindac the rectal cancer risk is obscure. Other studies suggest
that NSAIDs, e.g. aspirin, reduce the risk of colon carcinoma (Thun et al., 1991;
Giovannucci et al. 1994).
Surgical treatment
Surgery is the only effective treatment of FAP that prevents cancerous changes in
colorectal adenomas. Initially, surgical treatment was limited to local excisions of
rectal polyps. Thereafter local or segmental resections of the cancer were
performed but there was considerable mortality. During the 1940s advances in
anesthesia, antibiotics, electrolyte balance, and blood banks enabled major
surgery.
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The early reports of multiple polyposis of the colon and rectum stated that
polyposis is most safely treated by complete removal of the lower intestine in order
to eradicate the disease. However, an ileostomy is not without complications.
Therefore a more limited operation, colectomy and ileoproctosigmoideostomy
gained acceptance (Lockhart-Mummery, 1934). Colectomy became the standard
operation with a choice of colectomy and ileorectal anastomosis (IRA) or
proctocolectomy with an ileostomy (PC+I). IRA has been the operation of choice
for FAP in many centers since its introduction by Lockhardt-Mummery in 1918
(Lockhart-Mummery et al., 1956; Bussey et al., 1985; Bülow, 1987; Jagelman, 1991).
Spontaneous regression of rectal adenomas has been noticed after IRA (Hubbard,
1957), but the regression was only transient or partial (Watne et al., 1975; Feinberg
et al., 1988). Restorative proctocolectomy (RPC, proctocolectomy with ileal pouch-
anal anastomosis) became an alternative in ulcerative colitis and also in FAP after
pouch formation (Parks and Nicholls, 1978; Utsunomiya et al., 1980).
The pros and cons of IRA and RPC have to be evaluated on the basis of the
surgical results, balancing the recovery time, the morbidity rate, and the functional
outcome with the preventive effect against cancer. However, the choice of the
operation has been controversial (Setti-Carraro and Nicholls, 1996).
The type and time of the operation should be individualized on the basis of the
patient's age and the endoscopic and histological evaluation of the disease
(Phillips and Spigelman, 1996). Adult patients should be treated as soon as the
diagnosis is confirmed. Early colectomy is mandatory for severe dysplasia, large
adenomas, or rapidly growing adenomas. The decision is based on the desires of
the patient, the preference of the surgeon, and follow-up possibilities. The effect of
the surgery on the rest of the family must be remembered. Genetic testing may
identify a subset of families with more benign APC gene mutations (Vasen et al.,
1996; Soravia et al., 1998). IRA may be more acceptable for these patients without
an adverse effect on survival.
Proctocolectomy and ileostomy (PC+I)
PC+I has little place as long as the disease is benign and is used mainly in cases
with cancer in the lower third of the rectum (Jagelman, 1991). Conversion of IRA to
PC+I may be necessary with rectal cancer, especially in older patients.
Colectomy and ileorectal anastomosis (IRA)
After IRA, continence is maintained, problems with an ileostomy are avoided, and
sexual function is not impaired. However, before IRA, low rectal cancer must be
absent, and the number of polyps in the rectum limited so that they can be
managed by fulguration, follow-up should be possible, and examination of the
retained rectum must be possible with a rectoscope (Dozois, 1988). In addition,
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high anastomosis (between the ileum and the sigmoid colon) is associated with
increased risk of malignancy (Gingold and Jagelman, 1981).
IRA is relatively easy to perform, with low complication rates and good functional
results (Madden et al., 1991). The mandatory follow-up of the rectal stump after
IRA must vary according to the clinical and histological findings. Follow-up is not
free of complications, and, despite close follow-up, surveillance cannot always
prevent rectal cancer (Bussey et al., 1985; Nugent and Phillips, 1992).
Restorative proctocolectomy (RPC)
A few cases were treated by colectomy with removal of the rectal mucosa and an
ileoanal anastomosis over 50 years ago, but with little success (Dukes, 1952). A
reservoir proximal to the anastomosis gives better functional results than a strait
pull-through technique. Therefore, RPC became an alternative method after ileal
pouch formation (Parks and Nicholls, 1978; Utsunomiya et al., 1980; Williams,
1986).
RPC is recommended as the operation of choice for prophylactic surgery in FAP
(Kartheuser et al., 1996). Hand-sewn RPC eradicates all the potentially malignant
large bowel mucosa, while preserving continence. However, the surgical technique
in RPC is demanding, postoperative complications are more common, and the
functional results may be inferior to those after IRA. RPC is the primary operation
for teenagers, for patients with expected follow-up difficulties, and for patients
with large carpet-like polyposis of the rectum or with synchronous colonic or high
rectal cancer (Slors et al., 1989; Jagelman, 1991; DeCosse et al., 1992; Nugent and
Phillips, 1992; Nance, 1993; Ziv et al., 1995).
In FAP, ileal pouches may develop adenomatous polyps and are at risk of cancer
(Church et al., 1996). The natural course and the significance of pouch polyposis is
not preciseley known, but the pouches should be examined annually with
adequate biopsies, and stapled pouches at even closer intervals (Nugent et al.,
1993b; Wu et al., 1998a).
Desmoid disease
The treatment of desmoid tumors is problematic (Penna et al., 1993d; Church, 1994).
In restricted abdominal wall tumors, excisional surgery is straightforward but, when
diffuse, these may be hard to remove completely, and recurrence rates are high. In
mesenteric tumors, the hazards of bleeding and of short bowel syndrome are great
(Church, 1994). Aggressive surgery for intra-abdominal DT has been regarded as
unwise, and alternative medical therapies have been tried. In addition, DT may
24
preclude the conversion of IRA to RPC and further treatment of the rectal stump
(Penna et al., 1993d).  
There is evidence that the NSAID sulindac induces tumor regression (Tsukada et
al., 1992). Anti-estrogens (tamoxifen, toremifen) have also been used with some
success (Wilcken and Tattersall, 1991; Church, 1994). Cytotoxic chemotherapy and
radiotherapy may be used as last resort therapies but the results have been
variable and not without complications (Church, 1994).
Upper gastrointestinal tract
Conservative management has been regarded as sufficient for FGPs. Recently,
gastric adenocarcinoma arising from a fundic gland polyp was reported (Zwick et
al., 1997) and, therefore, large FGPs should be excised. Gastric adenomas may
undergo malignant transformation, and adenomas over 10 mm need treatment.
Adenomas can be removed by endoscopic polypectomy or electrocoagulation and
warrant surveillance at 6-month to 3-year intervals, according to the size and
histology of the adenomas (Sarre et al., 1987, Iida et al., 1988, Zwick et al., 1997) .
How and when to treat duodenal adenomas is a difficult question. Endoscopies,
preferably with a side-viewing endoscope, with numerous biopsies of the ampulla
and periampullary region should be done at least every three years (Sarre et al.,
1987). If there are large or dysplastic adenomas, endoscopies should be done
annually, and, with severe dysplasia or numerous large polyps, surgery should be
considered (Spigelman et al., 1989; Spigelman et al., 1994). Several endoscopic
methods can be used to treat duodenal adenomas (Saurin et al., 1999). Endoscopic
removal of all polyps is impossible. Complete clearance of duodenal adenomas by
duodenotomy fails because not all the microscopic adenomas can be removed and
the recurrence rate is 100% (Penna et al., 1993b).
In some cases, prophylactic duodenal or pancreaticoduodenal resection has been
recommended (Offerhaus et al., 1992; Penna et al., 1998). Pancreatico-
duodenectomy is a major operation with potentially severe complications and
cannot be justified in every case. However, recent reports have made claims of
minute morbidity and no mortality from pancreaticoduodenectomies (Saurin et al.,
1999). Besides this, other endoscopic and medical therapies should be evaluated




Most reasons for failures of surveillance are potentially correctable by a dedicated
registry that is responsible for notifying clinicians and patients about the timing of
surveillance procedures (Macrae et al., 1989). The location of the APC mutation
predicts, at least partially, phenotype expression of the disease (Lynch and Smyrk,
1998). Therefore, the surveillance and prophylactic management strategies should
be modified accordingly.
After bowel surgery
After IRA, patients are seen every 6 months, and thereafter at 3- to 12-month
intervals depending on the clinical and histological findings (Bülow, 1987). Ileal
adenomas may develop after colectomy and arise in pouches, even several years
after the operation. Furthermore, a stapled RPC fails to remove all the mucosa at
risk. Therefore, surveillance is essential. After RPC, annual follow-up of pouches
should be routine (Wu et al., 1998a).
Upper gastrointestinal tract
Before a decision can be made as to whether to screen for upper gastrointestinal
lesions, two important factors need consideration, i.e. the curability of the lesions
found at screening and the morbidity and mortality after treatment (Vasen et al.,
1990). The time-table of duodenal adenoma progression and the appropriate
intervals for endoscopic surveillance and biopsies are obscure. If duodenal
polyposis is of mild degree or absent, the proposed surveillance intervals of 3 to 5
years may be sufficient (Bülow, 1987; Debinski et al., 1995; Sawada and Muto,
1995). Patients who develop stage III or IV polyposis need closer surveillance with
yearly endoscopies, at least, and are candidates for prophylactic surgical
treatment.
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AIMS OF THE PRESENT STUDY
The objective of the present clinical study was to investigate the treatment
methods and results of the treatment in familial adenomatous polyposis. The
specific aims were:
1) to assess the functional results and complications following restorative
proctocolectomy and colectomy and ileorectal anastomosis in familial
adenomatous polyposis.  
2) to ascertain the risk of rectal cancer and the rectal excision rate after colectomy
and ileorectal anastomosis and the results of treatment of rectal polyps in the
retained rectum.
3) to determine the incidence of desmoid tumors and the outcome after treatment.
4) to evaluate the progression patterns of gastroduodenal polyposis and the
results of treatment of duodenal polyposis.




This study includes all the patients with FAP patients who were or are recorded in
the Finnish Polyposis Registry. The Registry was founded in 1984 with 160
patients belonging to 50 families (Järvinen et al., 1984). One to four further
pedigrees with 1-20 new polyposis patients have been detected annually. At
present, 108 pedigrees including 253 verified patients with FAP are recorded in this
Registry. Thus, the number of families and patients has altered during the study
period.
Type of operation (I)
The study included all the patients with FAP who had undergone RPC (33
patients) or IRA (99 patients) between January 1966 and June 1997. Before 1992, all
patients with FAP had IRA as the primary prophylactic operation, but after that
RPC was chosen as a rule, because a co-operative study (DeCosse et al., 1992)
including the majority of the IRA patients showed a very high secondary rate of
proctectomy. The RPC patients included 20 men and 13 women with a mean age of
34 years (range 6-58 years) at the operation. RPC was performed as a primary
procedure in 23 cases and secondarily after IRA in 10 cases. The indication for
secondary proctectomy was dysplastic changes in four, rectal carcinoma in three
(two Dukes C tumors, one with two Dukes A tumors), the patient's preference in
two, and suspicion of a perirectal tumor in one. There were 47 men and 52 women
in the IRA group and their mean age at the time of operation was 32 years (range
18-67 years).
The surgical technique of RPC included abdominal colectomy, proximal
proctectomy, mobilization of the small bowel, endoanal excision of the rectal
mucosa, a stapled ileal J-pouch, and a hand-sewn anastomosis. In three patients,
the rectum was everted for mucosal excision and one had stapled anastomosis
without mucosal excision. Diverting loop ileostomy was used for eight patients
(24%). All RPCs were done at university hospitals. IRA was preferably performed
with a low (5-10cm) ileorectal anastomosis. Sixty-four patients (64%) were operated
on at the Second Department of Surgery, Helsinki University Central Hospital; 35
had surgery at 15 other hospitals in Finland. The rectal stump was checked at 6- to
12-month intervals and clearly visible polyps were fulgurated to keep the rectum as
clear of polyps as possible.
For every patient, the peri- and postoperative outcome was evaluated from the
hospital records. In 22 patients, the functional outcome after RPC was assessed by
questioning about stool frequency (day and nighttime), continence, the need of a
protective pad or antidiarrhoeal medication and dietary restrictions. In addition,
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anal resting and maximal squeeze pressures and the length of the high-pressure
zone were determined by anal manometry. Finally, the patient's overall opinion
about anal function was asked. Identical assessment was performed for an equal
number of sex-matched patients with IRA by the investigator, with one exception.
The mean age of the patients with RPC was 32 years at the time of operation and 28
years in those with IRA. The mean postoperative follow-up at the time of
functional evaluation was 46 months in the RPC patients and 108 months in the
IRA patients. Of the 11 patients not available for functional assessment, two had
failure of anal preservation and five had been operated on less than 12 months
previously; four were not willing to come for an additional visit.
Incontinence was graded from 1: continent, 2: incontinent to flatus, occasionally
(<2/week) to a liquid stool, 3: incontinent to liquid stools, to 4: gross fecal
incontinence. Anal manometry was performed by the continuous pull-through
technique (2 mm/s). A polyvinyl catheter (Fr 8) with two opposite side openings
0.5 cm from the tip was perfused with saline and connected to a water-filled
pressure transducer and further to a recorder. The basal resting pressure and
maximal squeeze pressure were measured in centimeters of water. The length of the
high-pressure zone was measured directly from the manometry chart. The
functional outcome and anal manometry were assessed during the most recent
outpatient visit.
Rectal remnant after surgery (II)
By the end of 1995, the Finnish Polyposis Registry had data on 94 FAP pedigrees
with 333 affected patients. Nine families consisting of one solitary case with an
uncertain diagnosis of FAP were excluded as well as the 73 patients with a
deduced diagnosis on the basis of colorectal cancer and pedigree analysis. In
addition, 23 affected members living permanently abroad were excluded because of
insufficient follow-up data. The final study group consisted of 200 patients with
verified FAP. By the end of 1994, 100 patients (54 women, 46 men) had undergone
colectomy and ileorectal anastomosis; 63 patients had been operated on at the
Second Department of Surgery, Helsinki University Central Hospital and 37
patients in 15 other hospitals in Finland.
Since 1980, the standard operation has been a low ileorectostomy (5-10 cm from
anal verge) with a stapling device and removal or fulguration of all rectal polyps
under the same anesthesia. Patients were seen within 2 months postoperatively
and thereafter at 3- to 12- month intervall depending on the number and size of the
polyps. Histological examinations and polyp fulguration or removals had been
done at every follow-up, when appropriate. The cancer diagnosis was made after
histological verification. The results of the surgical and medical treatment were
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reviewed from the patients' records. The incidence of rectal cancer was calculated
from birth and from the IRA until the end of the study, the date of death, or the
first diagnosis of rectal cancer.
Desmoid tumors (III)
All clinically evident DTs with diameters of at least two centimeters were included
(n=29). Unequivocal DT was established by histopathological examination in 24
cases. In four patients, only fibromatous tumor was reported. One patient had no
operation or biopsy.  
The incidence of DT in our FAP cohort was calculated by person-year analysis,
beginning from birth until the end of the study, the date of death, or the date of
first diagnosis of DT. Similar calculations were also performed for the cumulative
risk of DT, using the Kaplan-Maier life-table analysis for both sexes. Considering
the precipitating factors proposed, the ages at colectomy and at pregnancies were
compared in patients with and without DT. In addition, the cumulative risks of DT
in patients who had undergone IRA were compared with those after PC. Finally,
the results of surgical and medical treatment were reviewed from the patient
records.
Duodenal polyposis (IV)
Upper gastrointestinal endoscopy has been part of the diagnostic work-up of FAP
since 1980. There were 98 patients who had had their first upper gastrointestinal
endoscopy at the Second Department of Surgery, Helsinki University Central
Hospital, and who had been or still were under surveillance at the Department by
the end of December 1997. All these patients were free of upper gastrointestinal
symptoms at the first endoscopy. There were 48 females and 50 males belonging to
50 families. The mean age at diagnosis of FAP was 29.5 (range 1-64) years and the
age at the time of the first upper endoscopy 33.3 (range 16-68) years. Colectomy or
proctocolectomy had been performed for 97 and one has thus far refused surgery.
The median follow-up time after the first examination was 11 years (range 0.2 to
17.4 years). In total, 341 endoscopies were done (median 3); 27 had only one
examination and 71 have had an endoscopy two to nine times.
Several biopsies were taken from all patients with polypoid lesions. In the
beginning of the study, random biopsies were not routinely taken at the first
endoscopy from a normal appearing mucosa. Since 1990, 65 patients have been
part of the multicenter DAF study (Bülow et al., 1995), which includes random
biopsies. The severity of duodenal polyposis was staged according to the
Spigelman classification (Table 2). Endoscopic surveillance was arranged at two-
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to three-year intervals, or more frequently if required, according to the clinical and
histological results. The duodenum was not routinely hypotonized.




Polyp number 1-4 5-20 20




Dysplasia mild moderate severe
Stage 0 = 0 points, stage I = 1-4 points, stage II = 5-6 points, stage III = 7-8 points,
stage IV = 9-12.
The operative technique included a mid-line laparotomy, Kocher manoeuver and
oblique duodenotomy. Adenomas over 4 mm in diameter were excised
submucosally and the smaller adenomas were fulgurated. Adenomas or tumors of
the ampulla of Vater were excised locally with sphincteroplasty in order to prevent
scarring of biliary or pancreatic ducts.
The cumulative risk of development of any duodenal adenomas, of advanced
adenomatosis, and of duodenal cancer were calculated from birth until the end date
of this study or the date of death, using Kaplan-Meier analysis. The cumulative
increase in duodenal adenomatosis (according to the Spigelman classification) was
calculated until the last endoscopy with increased stage, death, diagnosis of
duodenal cancer, or the end of this study.
Survival (V)
This study included all the patients with FAP recorded in the Finnish Polyposis
Registry by the end of June 1998. The data comprised 236 patients in 98 families
with verified FAP. The diagnosis had been defined by history, clinical examination,
histopathological assessment, and/or genetic testing. Of the patients 116 (51 men,
65 women) had been diagnosed on the basis of symptoms (probands) at a median
age of 36.8 years (range, 17-80 years), whereas 120 patients (67 men, 53 women)
had been diagnosed by family screening (call-up cases) at a median age of 22.8
years (range, 6-67 years).
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The postoperative cumulative relative survival rates were calculated according to
Verdecchia (Verdecchia et al., 1995) for 195 patients (102 probands and 93 call-up
cases). One patient, 6 years of age at operation, was excluded from postoperative
survival analyses for comparability since the other proband patients were older
than 15 years when operated on. Three patients with laparotomy only, six patients
without laparotomy, and 25 patients under surveillance were also excluded
because no operative treatment was undertaken. In addition, six patients operated
on before 1952 were excluded because survival and mortality probabilities for the
general population were available from 1951 onwards. The causes of death were
verified from registry charts, medical records, and death certificates, and from the
Central Population Register. Patients were followed up until the date of death or
the end of this study.
Statistics
The cumulative risks of DT, and of rectal cancer, the rectal excision rate, and the
development of any duodenal adenomas, of advanced adenomatosis, and of
duodenal cancer were calculated using the Kaplan-Meier analysis. The results
were analyzed using the t test for continiuous variables and the chi-square test,
Fisher’s exact test, the nonparametric paired sign test and the Mann Whitney U
test for discontinuous variables. The equality of interval-specific relative survival
rates between the patient groups was tested using a maximum-likelihood test
(Hakulinen et al., 1987). A probability of less than 0.05 was accepted as significant.
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RESULTS
Outcome of colectomy (I)
There was no operative mortality. The operation time and hospital stay were
significantly longer and blood loss and the transfusion rate significantly higher in
the RPC group, as shown in Table 3. The number of patients with postoperative
complications was 10 (30%) after RPC and 18 (18%) after IRA (p=0.14, chi-square
test).
One patient in the RPC group developed peritonitis following ileostomy closure. In
another case, anastomotic dehiscence could not be managed without excision of
the pouch, in spite of a protective ileostomy. One female patient refused closure of
the protective ileostomy for fear of incontinence.
Full assessment of anal function was possible for 22 RPC patients. Each of them
had a sex-matched control patient with IRA. The RPC patients were older than the
IRA patients (32.0 vs 27.8 years) and the follow-up time was significantly longer in
the IRA group (9.0 vs 3.9 years, p=0.0001). However, the general lifestyle did not
differ between the groups. There was no difference in the proportion of patients
having urgency, need for a protective pad, need for antidiarrheal medication, or
dietary restrictions. Two patients in each group with full functional analysis had
restrictions in sexual life. These restrictions were related to incontinence or bowel
frequency.
Eighty-two percent of patients following RPC and eighty-eight percent of patients
following IRA were completely satisfied with the postoperative state and
functional results. All the patients were capable of working and had no restrictions
in social life.
Rectal remnant after surgery (II)
Of 100 patients, nine developed cancer in the retained rectum 0.2 to 17 years after
IRA. The cumulative risks of rectal cancer after IRA were 4%, 5.6%, 7.9%, and
25.2% at 5, 10, 15, and 20 years (Fig. 3). The cumulative age-dependent risks of
rectal cancer were 3.9%, 12.8%, and 25.7% at the ages of 40, 50, and 60 years.
Twelve other patients had their retained rectum excised for benign conditions.
RPC was attempted in 7 patients, but it failed in two cases: in one because of
anastomotic breakdown and in the other because of poor sphincter function. The
mean time after IRA was 9.5 years (0.2 - 29), 9.2 years (0.2-17) in the cancer patients
and 9.6 years (4-29) in the non-cancer patients. The mean age at excision was 40
years (23 - 59), 44 years (34-59) in the cancer and 38 years (23-55) in the non-cancer
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Sex (men/women) 20/13 47/52
Age (years) 33.7 32.2
Follow-up (years) 3.2 11¶
Operation time (min) 216 † 182¶
Hospital stay (mean, days) 12 11¶
Blood loss (ml) 1253‡ 624¶
Transfusions (units) 3 (0-22) 0.9 (0-5)¶
Temporary ileostomy 8 -
Operative morbidity
 Hemorrhage 5 [4] 3 [3]*
 Anastomotic leakage 3 [3] 5 [5]
 Anastomotic stricture - 1
 Wound infection - 2
 Pneumonia 2 -
 Urinary tract infection 1 2
 Intra-abdominal abscess - 4 [2]
 Deep venous thrombosis - 1
 Protective ileostomy for
 complication(s)
4 5*
No complications 23 81
*, ¶ statistical significant: * Fisher's exact test, ¶ Mann-Whitney U test.
† 199 and 250 in primary and secondary RPC, respectively.
‡ 895 and 1970 ml in primary and secondary RPC, respectively.
Values in parentheses [ ] reflect patients who required surgery.
patients. The cumulative rectal excision rate (including all rectal cancer cases) after
IRA was 7.3%, 13.7%, 23.6%, and 36.6% at 5, 10, 15, and 20 years after operation,
and finally 73.8% at 29 years after IRA (Fig. 3). The cumulative age-dependent
rectal excision rates were 3.1%, 9.5%, 26.3%, and 44% at 30, 40, 50, and 60 years,
respectively. At present 21 patients have had rectal excision or rectal cancer and
seven have died from other causes; 72 remain in follow-up.
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Fulguration and/or removal of rectal polyps were performed 477 times in 76
patients. The number of treated polyps was less than five in six (8%), five to ten in
41 (54%) and more than ten in 29 (38%) patients. Nineteen patients have had no
detectable rectal polyps in repeated endoscopic examinations. Six patients had 12
attacks of postpolypectomy bleeding, but all were managed conservatively. One
rectal perforation after snare polypectomy was managed with antibiotics and
parenteral nutrition and another patient had distal ileal perforation needing
operation after fulguration of an ileal adenoma. Four patients had anal/rectal
strictures needing dilatation or sphincterotomy, probably due to scarring after
repeated fulgurations. The total number of patients with complications related to
rectoscopic check-ups was thus 12 (12%).
Twelve patients have had sulindac treatment for rectal polyps, with a complete
response in four, a partial decrease in four, no effect in two patients, and not
known in two. One of our patients had minor side-effects (nausea), which led to
cessation of sulindac within 12 months. He had rectal excision 4 months later
because of severe dysplasia in a rectal adenoma, but unexpectedly a stage C rectal
cancer was found in the operative specimen.
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Desmoid tumors (III)
The frequency was 29 in 202 patients (14%), 17 in women (17%) and 12 in men
(12%) - a female to male ratio of 1.4. The cumulative risk estimates were slightly
higher for women (23%) than for men (20%) with an average lifetime risk of
3.72/1000 person years. There were four “desmoid families” with two to five
members affected. DTs were observed in 21 of the 78 separate families (27%). All
the women developed their DTs when of childbearing age; however, only 10 of the
17 patients with DTs (59%) had had previous pregnancies, compared with 59 of 81
the FAP patients without DTs (78%). Of the patients with DTs, 83% had had
surgical procedures before diagnosis.
Five DTs were observed after 65 proctocolectomies (7.7%), compared with 14 cases
after 100 IRA (14%) - the remaining case occurred after abdominoperineal rectal
excision and nine before operation. The cumulative frequency figures showed no
significant difference between the two types of operation.
There was one example of complete spontaneous regression. Eleven patients with
abdominal wall tumors had complete or almost complete excisions without
complications. Recurrence developed in five instances (45%), and in two cases new
tumors appeared at other sites, the lower back muscles and the thoracic wall. A
mesenteric DT was observed in 17 patients, 16 of whom were operated on. Tumor
excision with bowel resection was performed in six cases (35%); three additional
patients had tumor excision later, after a primary by-pass procedure or biopsy. There
were two recurrences after excisional surgery (22%). Two patients (22%) had severe
complications after excisional surgery. Of the seven patients who had no tumor
excision, one needed surgery for renewed bowel obstruction and ureteric stasis. In
the other cases, the DTs have remained static for 3 to 9 years.
Medical therapy (sulindac, tamoxifen, toremifen) was given in 10 cases without
evidence of tumor regression: the tumor remained stable in three, and progressed in
seven, with further surgical treatment in four. However, there were no deaths due to
DT or their treatment during the mean follow-up time of 10 years after operation
(range 0.5 to 22 years). Of the 25 patients surviving, 15 have no evidence of
recurrence after complete excision, six others with known residual tumor have no
signs or symptoms of it, whereas four have symptomatic DT. Four patients died 3 to




At the first endoscopy, 53 (54%) of the 98 patients had duodenal adenomas, and
gastric fundic gland polyps were observed in 55 patients. The combined number of
patients with gastroduodenal polyposis at the first endoscopy was 75 (77%). During
the follow-up, duodenal adenomas developed in 25 (56%) of the 45 patients who
initially had no adenomas. Only seven patients had no duodenal adenomas after
repeated examinations, while 13 patients have not been re-examined. In most cases,
the severity of duodenal polyposis at the first endoscopy was mild.
Progression of the stage was observed in 52 (74%) of the 71 patients who came for
follow-up examinations. The stage of severity also tended to increase with
increasing age. The mean intervals between changes from stage 0 to I, stage I to II,
stage II to III, and stage III to IV were 5.7, 4, 6, and 11 years, respectively. Two
patients developed duodenal carcinoma at the ages of 38 and 42 years. Of the 98
patients, 78 had duodenal adenomas, including the two cases of duodenal carcinoma.
The cumulative lifetime risk of developing duodenal adenomatosis was 97%, stage
IV polyposis 30%, and duodenal cancer 4% (Fig. 4).
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Altogether 21 patients (21%) had prophylactic treatment for duodenal adenomas:
open surgical excision (15 patients), endoscopic snare excision (5 patients) or YAG
laser coagulation (one patient). The preoperative distribution of Spigelman stages
were: stage I 1, stage II 6, stage III 7, and stage IV 6 patients (stage unknown in
one patient). Ot the 17 patients eligible for postoperative endoscopic follow-up,
the Spigelman stage had decreased in 10 (59%), had increased in two (12%), and
was unchanged in five (29%) at the first postoperative endoscopy after a median
follow-up time of 2 years (range 0.16-6.8); the difference was statistically
significant (p=0.04, paired sign test). Nevertheless, after a median follow-up time of
6.8 years (range 0.4-15.1) there was no significant change in the Spigelman stage
(p=0.2, paired sign test) between the preoperative and the latest endoscopy.
During the follow-up, two patients underwent a second duodenotomy for clinically
and histologically severe polyposis 6 and 11 years after primary duodenotomy. In
spite of these re-polypectomies, stage III and stage IV duodenal polyposis were
diagnosed at the latest endoscopy. By the end of this study, four patients were
under consideration for further treatment.
Survival (V)
Colorectal cancer was detected in 76 of the 236 FAP patients (32%) at the time of
operation. The CRC rate was significantly less in the group of 120 call-up patients
(5; 4.2%) than in the proband group (71 vs 61%); (p<0.001). The stage distribution
of the tumors was also more favorable in the call-up group than in the probands, as
shown in Table 4.
Table 4. The frequency and stage of colorectal cancer at the time of initial
treatment of FAP.









5 (4.2%) 71 (61%) *
* p < 0.001, Fisher's exact test
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By the end of this study, all five call-up patients with CRC were alive after a median
follow-up of 15 years (range 12 -26 years). However, one male patient had
secondary RPC 11 years after IRA because of two Dukes A cancers in the rectal
stump. In comparison, 54 of 71 (76%) probands with CRC at diagnosis had died
after a median follow-up of 2.2 years (range 0-15 years) (49 of CRC, two of
postoperative pulmonary embolism, one of suicide, one of acute myocardial
infarction and one of renal failure). Only 17 (24%) probands were alive after a
median follow-up of 12.5 years (range 2-35 years).
Survival advantage was observed in favor of the call-up group over the probands
after colectomy or proctocolectomy. When survival figures relative to that of the
general population were calculated, the difference between the two groups remained
unchanged and  survival of the call-up group did not differ from that of the general
population up to 18 years after colectomy (Fig. 5).
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By the closing date of the study, 10 of the 120 call-up patients (8.3%) and 58 of the
116 probands (50%) had died. The majority of deaths were attributable to FAP, 60
of the 68 cases (88%): seven of 10 (70%) in the call-up group compared with 53 of
58 in the probands. CRC present at the time of primary colectomy caused 43 deaths
in the proband group but none in the call-up patients. However, rectal stump
cancer caused four deaths in the call-up patients and seven deaths in the
probands. The other FAP-related causes of deaths were periampullary (duodenal)




The choice between IRA and RPC as a prophylactic operation for FAP is not an
easy issue (Setti-Carraro and Nicholls, 1996). Colectomy with ileorectal
anastomosis may be associated with a lower risk of postoperative morbidity and
functional problems. However, according to present results, the high long-term
cancer risk of the rectal stump makes a secondary proctectomy necessary in at
least half of the patients.
The early complication rate of 30% following RPC was close to that observed in
other comparative studies (Ambroze et al., 1992; Kartheuser et al., 1996; Tonelli et
al., 1997). Late complications occurred slightly more often after IRA, mainly on
account of more frequent small bowel obstruction. RPC is technically more
demanding, with a longer operation time and extensive blood loss, especially in
secondary cases (Nyam et al., 1997). Long-term restoration of adequate anal
function may be as good as after primary RPC and IRA, and function improves
with time (Penna et al., 1993a).
The functional outcomes following RPC and IRA in regard to anal pressure, bowel
movements, incontinence, and sexual life were similar, as also reported from the
Mayo Clinic (Fazio et al., 1995). In the other comparitive study, the functional
results were in favor of IRA at St Mark's (Madden et al., 1991) and, recently, in a
large Dutch study (van Duijvendijk, 2000). The mucosal remnant remaining after
stapled anastomosis carries the same risk for cancer as the original disease
(Wolfstein and Neumann, 1982; Tsunoda et al., 1990). Therefore mucosectomy
should always be performed (O'Connell and Williams, 1991; Kartheuser et al.,
1996). Even so, the risk may not be totally eliminated, since invasive cancer has
been observed developing either from the preserved transitional zone or from
retained mucosal remnants (Hoehner and Metcalf, 1994; von Herbay et al., 1996).
The quality of life was not restricted by RPC, as reported earlier (Nyam et al., 1997;
Tonelli et al., 1997). In a recent study, however, the quality of life was similarly and
significantly worse after IRA and RPC than that of the general population (van
Duijvendijk, 2000). The degree of satisfaction is correlated not only with the
objective outcome but also with personality and lifestyle (Fujita et al., 1992;
Daniels et al., 1999). FAP patients need to be carefully counselled before RPC so as
to understand that bowel habits will be far from normal (Körsgen and Keighley,
1999).
The present results are in favor of primary RPC with mucosectomy and hand-sewn
anastomosis without diversion as the operation of choice in FAP. RPC requires
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surgical experience to guarantee acceptable results and therefore necessitates
centralization of these operations to university hospitals or other large centers. It
is important that patients know that occasionally RPC may be technically
impossible because of intra-operative finding of mesenteric fibromatosis or a DT
(Church, 1995).
Improved genetic testing may identify a subset of families with more benign
phenotypic expressions of APC gene mutations, in which IRA may be acceptable
(Bertario et al., 1994; Vasen et al., 1996; Wu et al., 1998b). The decision for
prophylactic surgical treatment should be based on clinical factors and molecular
diagnosis in the near future (Soravia et al., 1998; van Duijvendijk, 2000). In cases
with small numbers of adenomas in AFAP, polypectomy and colonoscopic
surveillance have been proposed as an option (Lynch and Smyrk, 1998).
The rectal stump
The cancer risk after IRA and its significance are debated. The rectal cancer risk of
25% at 20 years after operation comes close to the estimates from Japan (24% at 15
years) and from the Mayo Clinic (26% at 20 years) (Bess et al., 1980; Iwama and
Mishima, 1994). In three other studies, there are clearly lower risk rates, from 13 to
15% at 25 years after IRA (Feinberg et al., 1988; DeCosse et al., 1992; Nugent and
Phillips, 1992). This may be due to differences in patient characteristics, variable
follow-up policy, or even to the wide confidence limits of estimates related to few
cases with follow-up times for more than 20 years.
The justification for IRA is also influenced by the difficulties connected with
regular rectal examinations. Polypectomies and fulgurations caused bleeding
episodes and two patients had a bowel perforation. Increased by four cases with
anorectal stricture, the total frequency of complications at follow-up was 12 (12%).
More importantly, uncontrollable rectal adenomas, severe dysplastic change, or
fear of cancer necessitated rectal excision in 12 patients of the present series. The
total cumulative proctectomy rate reached 74% at 29 years after IRA. De Cosse et
al. reported a cumulative total proctectomy rate of 44% at 25 years (DeCosse et al.,
1992). In a recent registry analysis, the risks of secondary proctectomy on account
of rectal cancer or for other reasons were 26% and 34%, respectively, by the age of
65 years (van Duijvendijk, 2000).
In the series at St. Mark’s Hospital, the cumulative rectal cancer rate remained at
10% until the age of 50 years, but increased sharply to 29% by 60 years of age
(Nugent and Phillips, 1992). They proposed IRA as the operation of choice for
patients under 30 years and RPC for older patients and those who had undergone
IRA. There was no steep rise in the age-dependent rectal cancer rate in this study
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at any time, and seven of nine patients developed rectal cancer before the age of
50 years. The rectal cancer risk of 13 to 26% within the next 20 years is of a matter
great concern, no matter how safe and simple the primary operation is. Not all
patients can be kept under control and, even in those under close control, the
cancer tended to be more widespread (van Duijvendijk, 2000). Furthermore, a
second-stage restorative proctectomy may not result in perfect functional
outcome, or may be impossible in cases of pelvic fibromatous adhesions or
desmoids (Penna et al., 1993a). A planned strategy of two prophylactic operations
doubles the risks of the operations and may also increase the risk of DT.
Sulindac reduces adenoma formation in FAP, and, when taken by mouth or with
rectal application, often causes the disappearance of rectal polyps (Labayle et al.,
1991; Nugent et al., 1993a; Winde et al., 1995; Giardiello et al., 1996). Sulindac
caused at least partial regression of rectal polyposis in over half of the present
patients, without side-effects. One patient had an advanced rectal stump cancer
after cessation of sulindac, as has also be reported by others (Niv and Fraser,
1994; Lynch et al., 1995b). Regression is not always complete or permanent, and
medical treatment does not replace prophylactic surgery (Giardiello, 1996).
Endoscopic surveillance is necessary even during prophylactic medical treatment.
It should be noted that the marketing licence of sulindac (Clinoril®) in Finland
ceased in September 1999. Sulindac is available only with permission for each
patient from the National Agency for Medicines. Whether or not the new specific
cyclooxygenase inhibitors (COX-2) are effective remains to be seen (Hawk et al.,
1999).
The high cumulative risk of rectal cancer, 25% at 20 years after IRA, combined
with the much higher total proctectomy rate (74% in 29 years) indicates that IRA is
not a satisfactory long-term treatment. The outcome may be better when sulindac
is added. Otherwise, the retained rectum has to be excised prophylactically in
middle age. These results underline the importance of RPC as a main option in
most cases of FAP.
Management of desmoid tumors
When the colon cancer risk is reduced, the importance of the DT increases, as may
its frequency. The figure of 14% is close to previous frequencies, but by the age of
60 years, the cumulative probability reaches 21%. A person-year analysis resulted
in an incidence of 3.72 per 1000 person years, 1240 times the risk for the general
population, which was slightly more than reported from the Johns Hopkins
Hospital (Gurbuz et al., 1994).
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Consistently with previous reports, the risk of DT was greater in females, with a
female-to-male ratio of 1.4 (Iwama et al., 1993; Gurbuz et al., 1994). The cumulative
lifetime risk was 23% for women and 19% for men. Klemmer et al. found a similar
difference, but lower risk figures (Klemmer et al., 1987). Hormonal influences, e.g.
pregnancies, have been thought to explain the greater DT frequency in women
(Reitamo et al., 1986). However, pregnancies were not more frequent in the present
DT patients than in the women without DT. The present was unable to detect any
measurable estrogen or progesterone receptors in three DTs, in contrast to
Reitamo et al. (Reitamo et al., 1986), who demonstrated a low estrogen receptor
content in the DT of one male patient.
Surgical trauma precedes the development of most DTs, i.e. in 83% in our patients.
However, in FAP surgery is unavoidable. Prophylactic colectomy at a very early
age may increase the risk of DT, at least in known “desmoid families”. There were
no significant differences in the DT risk after different surgical procedures.
Interestingly, all five mesenteric DTs after PC occurred in cases of conventional
ileostomy, and none was observed after 20 RPC. This may reflect the small number
of cases and short follow-up after the pouch procedure, but supports the view that
RPC does not increase the risk of DT (Penna et al., 1993d).
Most authors agree that abdominal wall and other superficial DTs can often be
cured by wide excision, especially when the tumor is small (Richards et al., 1981;
Farmer et al., 1994; Church, 1995; Griffioen et al., 1998). Complete clearance of the
abdominal wall DT was achieved in eight of the 11 cases operated on, and there
was one case with complete spontaneous regression. However, local recurrence
was common (45%) leading to re-excisions, and two patients developed new DTs
at other sites. Some recurrent cases are probably new tumors at multiple sites near
to the original one.
A large mesenteric DT is difficult to deal with, especially when it is at the
mesenteric root, making complete resection hazardous (Church, 1995; Griffioen et
al., 1998). Patients with relatively small DT masses or no obstructive symptoms
have been operated on with small bowel or ureteric by-pass with a stable situation,
as observed earlier (Church, 1995). Excisional treatment was undertaken either in
suitable cases or when no other choice was seen. There were two recurrences
(22%), clearly less than the high recurrence figures, from 50 to 85%, reported earlier
(Berk et al., 1992; Farmer et al., 1994; Rodriguez-Bigas et al., 1994). Furthermore, in
spite of two life-threatening complications, there were no postoperative deaths.
This contrasts with the experience of others reporting a perioperative mortality of
50% or major morbidity of 60% (Jones et al., 1986; Farmer et al., 1994).
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DTs are insensitive to radiation therapy, which is therefore of limited value in the
treatment (Jones et al., 1986). Noncytotoxic medical treatment may sometimes be
effective in the longterm (Tsukada et al., 1992). The present study, consistently
with other reports, could not demonstrate any measurable regression in 10 cases
treated with sulindac and/or antiestrogens (Itoh et al., 1988; Penna et al., 1993d).
Likewise, there are a reports of favorable responses to high-dose cytotoxic
chemotherapy (Patel et al., 1993; Lynch et al., 1994; Schnitzler et al., 1997). Further
experience with the same or similar regimens has given disappointing results with
few responses but a high frequency of severe toxicity, and even deaths (Tsukada
et al., 1991).
It is impossible to give any uniformly applicable recommendations for prevention
or medical treatment of DTs. Desmoids and their complications have been reported
as the second most common cause of death after colectomy in FAP (Arvanitis et
al., 1990; Iwama et al., 1993; Belchetz et al., 1996). There were no deaths related to
DTs in this study, in accordance with the Danish experience (Søndergaard Calle et
al., 1999). The St Mark's group (Clark and Phillips, 1996) has proposed a treatment
protocol for DT. It consists of imaging studies, initial treatment with sulindac for 6
months, thereafter toremifene when needed, and consideration of chemotherapy.
Surgery is reserved for obstructive complications and for abdominal wall DTs.
Every case of mesenteric DT seems to be different. Some authors have taken the
position that excisional treatment of mesenteric DT should be totally abandoned
(Farmer et al., 1994; Church, 1995). However, this study showed that there are
cases with no other possibility and that a recurrence is not the rule. One aspect
supporting surgery, even excisional surgery, is the absence of other treatment
options.
Treatment of gastroduodenal lesions
The cumulative detection rate of duodenal adenomas was 97% even without a
side-viewing endoscope and random biopsies. In previous studies, the detection
rate has varied between 66 and 92% at the initial examination (Spigelman et al.,
1989; Church et al., 1992). The use of side-viewing endoscope, multiple biopsies,
and frequent re-examinations will probably demonstrate duodenal adenomas in
every FAP patient.
The stage of the duodenal adenomas progressed in the majority (74%) of those
patients who had follow-up examinations. Stage IV duodenal adenomatosis,
implying the highest cancer risk, has been detected in approximately 10% of all
patients with FAP (Spigelman et al., 1989; Bülow et al., 1995), as in the present
series (8%). The cumulative incidence of stage IV disease, however, reached 30%
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at the age of 65 years. Assuming that all FAP patients develop duodenal
adenomas, which progress to stage IV in 30% of cases, the low incidence of
duodenal cancer is surprising. The cumulative cancer incidence was 4%, being
consistent with the reported incidence of 3 to 4% (Vasen et al., 1997). The
progression of the adenoma-carcinoma sequence is probably slower in the
duodenum than in the colon (Offerhaus et al., 1992; Spigelman et al. 1994). On the
other hand, CRC mortality has possibly hidden other, less common, problems such
as duodenal cancer. Therefore, improving control of the CRC by family screening
and prophylactic colectomy will probably result in an increase in the rate of
duodenal carcinoma.
The occurrence and severity of periampullary neoplasms segregates in families
without any relation to a specific APC mutation (Sanabria et al., 1996). Thus,
knowledge of the polyp status of a family predicts the risk and modifies the
screening of family members. The extent to which surveillance and subsequent
treatment of severe duodenal polyposis benefit FAP patients is not known (Sarre
et al., 1987; Spigelman et al., 1989; Norfleet, 1992; Debinski et al., 1995; Marcello et
al., 1996). In a decision analysis, Vasen and co-workers concluded that regular
surveillance could lead to an increase in life expectancy of 7 months when
pancreaticoduodenectomy is performed in cases with stage IV polyposis or early
cancer (Vasen et al., 1997).
Several endoscopic methods can be used to treat advanced duodenal adenomas
(Saurin et al., 1999). The effectiveness of endoscopic mucosal resections, laser
therapy, argon plasma coagulation, and photodynamic therapy remains to be
confirmed by prospective studies. None of our patients who had prophylactic
excisions for advanced duodenal adenomas has developed duodenal cancer. In a
control endoscopy, a significant decrease in the average stage was still
demonstrable after two years. Unfortunately, re-growth of the adenomas occurred
always, as observed earlier (Penna et al., 1993b).
In theory, stage III or IV will be reached within a mean of 10 to 20 years in all cases
after open duodenotomy. In selected cases with stage IV adenomatosis, there may
be a place for prophylactic pancreaticoduodenectomy with or without pylorus
saving, at least in young patients with severe disease or in those who need re-
operation after excisions (Chung et al., 1995; Causeret et al., 1998; Penna et al.,
1998) but this is controversial (Griffioen et al., 1998).
Cell kinetic studies have shown proliferation abnormalities in the duodenal
mucosa, there being two subgroups with different risks of duodenal neoplasia
(Santucci et al., 1997). Duodenal adenoma formation seems strongest at the site
around the papilla of Vater or at the site where the mucosa is exposed to high bile
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concentrations (Spigelman et al., 1989; Debinski et al., 1995). Therefore, adenomas
may appear in the upper jejunum near to the new bile duct anastomosis at a similar
frequency after excision of the duodenum as after local excisions through a
duodenotomy. Medical treatment in the form of some nonsteroidal anti-
inflammatory drug might give a better response, but treatment with sulindac has
given conflicting results in the control of duodenal adenomas (Nugent et al.,
1993a; Richard et al., 1997; Wallace and Phillips, 1999). Chemopreventive agents
have not demonstrated definitive efficacy against duodenal adenomas (Hawk et al.,
1999).
Survival in familial adenomatous polyposis
The protective effect of screening and prophylactic colectomy is obvious. The
percentage of patients with CRC was 4% in the call-up group and 61% in
symptomatic group at the time of initial treatment, which is in accord with earlier
reports (Alm and Licznerski, 1973; Bülow, 1986; Berk et al., 1987; Vasen et al., 1990).
Almost half of the CRCs in probands were already disseminated.
The majority (79%) of deaths were caused by CRC, corresponding the previously
reported figures of 58-81% (Arvanitis et al., 1990; Iwama et al., 1993; Bertario et al.,
1994). The second most common cause of death in the present series was rectal
stump cancer, comprising nearly one fifth of all FAP-related causes. In addition,
care of the rectal stump may cause difficulties, and even deaths. Rectal stump
cancer can be prevented by performing the first operation with RPC. Therefore,
RPC has been recommended as the operation of choice for most FAP patients
(Ambroze et al., 1992; Kartheuser et al., 1996).
Survival after prophylactic colectomy equaled that of the general population for at
least 18 years, as observed earlier (Søndergaard Calle et al., 1999). On the other
hand, Nugent et al. observed a more than three-fold relative risk of death in FAP
patients after colectomy and ileorectal anastomosis (Nugent et al., 1993c).
Corresponding to the Danish experience, there were no deaths related to desmoid
disease (Søndergaard Calle et al., 1999) even though such cases are well-known in
other centers (Arvanitis et al., 1990; Iwama et al., 1993; Nugent et al., 1993c;
Belchetz et al., 1996). Postoperative mortality was not observed in the call-up
patients, but did occur in two probands who had CRC at the time of primary
colectomy.
The experience of the Finnish Polyposis Registry is limited, with a median follow
up of about 10 years only in the call-up group. As the median age at the time of
colectomy was 27 years, the expected follow up time may approach 50 years.
Therefore, more cases of extracolonic cancer and rectal stump cancer can be
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expected, especially at the ages of 50 to 60 years (Nugent and Phillips, 1992;
Nugent et al., 1996). Moreover, even when deaths from colorectal cancer remain
constant or decrease in frequency, it is likely that death rates from extracolonic
manifestations of FAP will continue to increase (Bertario et al., 1994; Belchetz et al.,
1996).
Surveillance
The screening and surveillance recommendations in an FAP family with a known
mutation should be based on the site of the mutation (Brensinger et al., 1998; Wu
et al., 1998b). However, differences in the APC mutation sites alone cannot
completely account for the intra- and interfamilial variation of the phenotype. The
presence of a modifier gene or genes and environmental factors influence the
phenotypic expression of the APC. The advances in molecular genetics may lead
to future identification of high-risk individuals with different schedules for
screening, surveillance, and treatment.
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CONCLUSIONS
1. The results favor primary restorative proctocolectomy, usually in one stage,
despite the risk of less perfect functional results in some cases.
2. Colectomy and ileorectal anastomosis is not a satisfactory long-term treatment
for patients with familial adenomatous polyposis because of the high risk of
rectal stump cancer (25%/20 years) and the 74% risk of rectal excision.
3. The cumulative lifetime risk of a desmoid tumor is 21%. Medical treatments of
desmoid tumors have limited success. Thus, surgery has an important role in
the treatment of both abdominal wall and mesenteric desmoid tumors.
4. Nearly all patients with familial adenomatous polyposis will develop duodenal
adenomas in the endoscopic follow-up. Surveillance and subsequent
prophylactic surgical treatment are beneficial. Local endoscopic treatment is
rarely possible and the choice is mostly between open duodenotomy and
pancreaticoduodenotomy even though recurrence of the adenoma is probable
after either procedure.
5. Screening and prophylactic surgery have improved the prognosis of patients
with familial adenomatous polyposis so that, for nearly 20 years, the survival
equals that of the general population. Centralization of screening, diagnosis,




Familial adenomatous polyposis is an autosomally dominant inherited cancer
predisposition syndrome. The disease is characterized by multiple adenomatous
polyps with an inevitable risk of colorectal cancer. Various extracolonic
manifestations may also appear. The aim of the study was to investigate
therapeutic strategies, results of treatment, and survival of patients with FAP, on
the basis of the data from the Finnish Polyposis Registry.
The justification for colectomy and ileorectal anastomosis (IRA) as the primary
treatment for FAP remains questionable because of the rectal cancer risk. The
cancer risk and the need for rectal excision were estimated in 100 FAP patients. The
cumulative risks of rectal cancer after IRA at 5, 10, 15, and 20 years were 4%, 5.6%,
7.9% and 25.2%. The corresponding rectal excision rates were 7.3%, 13.7%, 23.6%,
and 73.8%. Age-dependent rectal cancer risks at 40, 50, and 60 years were 3.9%,
12.8% and 25.7%, and rectal excision rates were 9.5%, 26.3% and 44%, respectively.
Sulindac caused at least partial regression of rectal adenomas in 71% of patients,
without major adverse effects, but the long-term effects of sulindac and its impact
on malignant transformation of rectal adenomas are not known. The results favor
RPC as the primary operation for FAP. RPC requires sufficient surgical experience
to be certain of acceptable results and therefore necessitates centralization of
prophylactic operations to university hospitals or other large centers.
The operative and functional outcomes were compared in 99 IRA and 33 RPC
patients. Primary RPC is the operation of choice for most patients with FAP when
the long-term outcome is taken in account. In the future, improved genetic testing
may identify a subset of families with more benign adenomatous polyposis gene
mutations, and for these patients IRA may be more acceptable. On the other hand,
for those patients in whom the rectum retained and who develop multiple rectal
adenomas, treatment with sulindac may offer a possibility to reduce the rectal
cancer risk, but the long-term efficacy of this treatment is not yet known.
The incidence and treatment of desmoid tumors were analyzed in 202 FAP patients.
DTs were observed in 29 cases, representing a frequency of 14% and a cumulative
probability of 21%. All abdominal wall and 56% of mesenteric DTs were excised,
with recurrence rates of 45% and 22%, respectively. This study failed to
demonstrate regression of DTs with noncytotoxic medical treatment, cytotoxic
chemotherapy, or radiation therapy. According to these results surgery is the
preferred treatment method when the risks are taken into account.
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In the prospective follow-up study, 98 patients underwent at least one upper
endoscopic examination. In these endoscopic follow-ups nearly all FAP patients
are found to have developed duodenal adenomas. There was progression of the
stage of duodenal adenomatosis in 74% of patients followed up, and stage IV
disease developed by the age of 65 years in 30%. Even though the duodenal
cancer incidence has been low, there are indications that surveillance, followed
when necessary, by prophylactic surgical treatment are beneficial. Local
endoscopic treatment is rarely possible and the choice is mostly between open
duodenotomy and pancreaticoduodenectomy, even though adenoma recurrence is
probable, whichever procedure is chosen.
The mortality rates and causes of death were studied in all 236 FAP patients
included in the Finnish Polyposis Registry. Centralized registration of FAP
patients, screening for at risk family members, and prophylactic colectomy have
improved the prognosis of FAP patients, so that their life expectancy may reach
that of the general population for almost 20 years after surgery. However, there is
excess mortality in the long term, e.g. because of periampullary cancer or gastric
cancer developing from gastroduodenal adenomas or because of rectal stump
cancer. Further improvement of the prognosis may be possible with more frequent
application of restorative proctocolectomy instead of colectomy and ileorectal
anastomosis and with regular upper GI-tract endoscopies.
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